Drug firm Dr Reddy's Laboratories today said it has launched generic antihistamine desloratadine tablets in the American market.
The company has launched generic desloratadine orally disintegrating tablets in the strengths of 2.5 mg and 5 mg in the US market on January 24, 2013, Dr Reddy's Laboratories (DRL) said in a statement.
This follows approval of its abbreviated new drug application (ANDA) by the US Food & Drug Administration (USFDA), it added.
The tablets are bio equivalent generic version of Schering Corp's Clarinex Reditabs tablets, DRL said.
"Clarinex Reditabs brand had US sales of approximately $5.3 million for the most recent twelve months ending November 2012 according to IMS Health," it added.
Shares of Dr Reddy's Laboratories today closed at Rs 1,942.55 on BSE, up 0.68% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app